Evidence map›Paper›PMID 33649501›Full record

ArticleScientific reports2021

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors.

Hui-Jen Tsai, Her-Shyong Shiah, Jang-Yang Chang, Wu-Chou Su, Nai-Jung Chiang, Li-Tzong Chen

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Hui-Jen TsaiNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. hjtsai@nhri.org.tw.
Her-Shyong ShiahDivision of Hematology and Oncology, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan.
Jang-Yang ChangDepartment of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 1F No 367, Sheng-Li Road, Tainan, 70456, Taiwan.
Wu-Chou SuDepartment of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 1F No 367, Sheng-Li Road, Tainan, 70456, Taiwan.
Nai-Jung ChiangNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Li-Tzong ChenNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
National Cheng Kung University Hospital · TWNational Cheng Kung University · TWNational Health Research Institutes · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

S-1, an oral pyrimidine fluoride-derived agent, is effective against various cancers. Sorafenib, an oral multikinase inhibitor, was found to prolong the survival of various cancers and enhance the cytotoxicity of chemotherapeutic agents. We conducted a phase I dose escalation study to determine dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of S-1 when combined with sorafenib for refractory solid tumors. Eligible patients received escalating doses (30, 35, and 40 mg/m

Indexed as

AdultColonic NeoplasmsDisease-Free SurvivalFemaleHumansMaleMiddle AgedSorafenibSurvival RateSorafenib

Identifiers

PMID33649501
PMCPMC7921110
OpenAlexW3135000384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.